Ex-HHS Official: $19.50 May Not Be Benchmark For COVID-19 Vaccines

By John Wilkerson / July 24, 2020 at 3:27 PM
Wall Street analysts assume the $19.50 per dose price for Pfizer’s coronavirus vaccine candidate sets a benchmark, but a former HHS vaccine official cautioned that HHS may insist on a much lower price for future purchases. The initial contract may pay a “speed premium” for extremely fast development, and Pfizer has not taken federal funding like other companies. HHS announced this week that it will pay $1.95 billion for 100 million doses of a coronavirus vaccine candidate being developed by...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.